ClinicalTrials.gg

Program

TXN10128

A development code.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Txinno Bioscience.

Furthest: phase 2, since Oct 26, 20262 company-led studies, 2 open or runningNext primary completion: Sep 30, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Txinno Bioscience22 open or runningphase 2since Oct 26, 2026Jul 20, 2023Sep 30, 2028phase 2 · NCT07933055

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 20, 2023First study: phase 1 study in Locally Advanced (Unresectable) or Metastatic Solid TumorsFirst studyNCT05978492 · 96 planned · Korea, Republic of
  2. Oct 26, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungPhase 2 reachedNCT07933055 · 104 planned · South Korea

Ahead

  1. Sep 30, 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07933055

TargetBeta

ENPP1 →read by rule
“A Multicenter, Open-label, Phase 1 Dose Escalation and Expansion Study of TXN10128, an Inhibitor of ENPP1 as Monotherapy and Combination Therapy With Irinotecan or Paclitaxel in Locally Advanced or Metastatic Solid Tumors”study text, by rule · the study

Other programs on ENPP1

ProgramCompanyFurthest phaseStudies
ENPP1 Inhibitor RBS2418ruleriboscience-llcphase 23

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07933055Carcinoma, Non-Small-Cell Lung · South Korea2RecruitingSep 30, 2028104
NCT05978492Locally Advanced (Unresectable) or Metastatic Solid Tumors · Korea, Republic of1RecruitingDec 31, 202596

How it is read

Names in the registry

  • “TXN10128”, 2 entries

Codes read as this program: TXN10128.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.